ARCH Venture Partners
Deep science and technology venture firm focused on life sciences, energy, and information technology.
ARCH is the gold standard for biotech investing but they're not messing around with tourist entrepreneurs. They want founders who understand that building breakthrough science takes 7-10 years and $100M+ in capital. Nelsen has an almost mystical ability to spot winning biotech platforms early, but he'll grill you on the science until you cry. They're incredibly supportive if you make the cut - legendary for helping companies navigate FDA approval processes and building world-class management teams. Just don't expect quick exits or patience for pivoting away from hard science.
- —Best for: Deep tech and biotech founders with breakthrough science and long-term vision
- —Watch out for: They have zero tolerance for hand-wavy science or unrealistic timelines
- —Known for: Unmatched biotech expertise and helping companies through complex regulatory processes
ARCH focuses on early-stage companies at the intersection of physical and digital worlds, particularly in biotech, materials, and deep tech. They look for breakthrough technologies that can transform entire industries through scientific innovation.
Primarily Series A and B, with some seed investments. Heavy emphasis on biotech/pharma, materials science, energy, and enterprise software with deep technical moats. Portfolio skews toward companies requiring significant R&D and longer development timelines.
The biotech legend who's been at ARCH since 1993. Former McKinsey consultant turned life sciences investor with an incredible track record in building category-defining biotech companies. Founders describe him as brilliant but demanding.
Deep enterprise software and infrastructure background, joined in 2006. Former operating executive who understands the nuts and bolts of building scalable tech companies. Known for being hands-on with portfolio companies.
Former Goldman Sachs banker who moved into healthcare investing. Joined ARCH in 2013 and focuses on life sciences and healthcare IT. Respected for her financial discipline and market timing.
Have a specific question about ARCH Venture Partners?
Ask Bernie →